Detalles de la búsqueda
1.
Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse.
J Headache Pain
; 25(1): 26, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38408888
2.
Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.
Headache
; 63(2): 264-274, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36633219
3.
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
Headache
; 63(4): 484-493, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36753057
4.
Using artificial intelligence to identify patients with migraine and associated symptoms and conditions within electronic health records.
BMC Med Inform Decis Mak
; 23(1): 121, 2023 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37452338
5.
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
Cephalalgia
; 42(10): 1005-1012, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35332807
6.
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
Cephalalgia
; 42(8): 696-704, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35302389
7.
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.
BMC Neurol
; 22(1): 251, 2022 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35804294
8.
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
BMC Neurol
; 22(1): 394, 2022 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36284281
9.
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
BMC Neurol
; 22(1): 205, 2022 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35659622
10.
Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
Headache
; 62(5): 558-565, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35524405
11.
Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
Headache
; 62(6): 690-699, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35466430
12.
Eptinezumab for migraine prevention in patients 50 years or older.
Acta Neurol Scand
; 145(6): 698-705, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35218203
13.
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.
J Headache Pain
; 23(1): 23, 2022 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35130836
14.
Development and validation of a novel model for characterizing migraine outcomes within real-world data.
J Headache Pain
; 23(1): 124, 2022 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36131249
15.
Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.
J Headache Pain
; 23(1): 29, 2022 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35189811
16.
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study.
J Headache Pain
; 23(1): 91, 2022 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35902796
17.
Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.
J Headache Pain
; 23(1): 115, 2022 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36068494
18.
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
J Headache Pain
; 23(1): 22, 2022 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35130832
19.
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
BMC Neurol
; 21(1): 126, 2021 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33740902
20.
Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
Headache
; 61(5): 766-776, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34013992